Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity
- 1Department of Medical and Pharmaceutical Bionanotechnologies Institute of Cellular Biology and Pathology “Nicolae Simionescu” Bucharest Romania
Abstract
Tumors often develop an immune phenotype that closely resembles that of their host, fostering strong immune tolerance. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS). This oxidative vulnerability can be exploited by using ROS‐enhancing compounds that oxidize tumor antigens, offering a promising approach to disrupt immune tolerance and convert immunologically “cold” tumors into “hot” ones. This perspective synthesizes recent findings focused on controlled ROS generation within the tumor microenvironment to induce tumor destruction and stimulate antitumor immunity. While many ROS enhancers are based on small molecules, liposome‐based targeted delivery systems offer a versatile and efficient platform for tumor‐selective transport. Among these, peptide‐functionalized nanovehicles (liposomes and lipid nanoemulsions) stand out for their enhanced targeting precision and design flexibility, allowing tailored delivery strategies. Advances in the design of peptide‐functionalized nanovehicles reveal their potential to trigger ROS‐dependent immune activation, highlighting their promise for integrated immuno‐oncology approaches. By combining targeted delivery with oxidative modulation, these nanoplatforms provide a powerful strategy for reprogramming the tumor microenvironment and amplifying immune responses against therapy‐resistant tumors.
Related
- A Pathway-Economical Synthesis Enabling Systematic Evaluation: Enantiodivergent Access to Aspidosperma Alkaloids Unlocks Divergent Antitumor Mechanisms.
- BF2-Boracycles Enabling Selective ortho-Mono Hydrogen Isotope Labelling
- Nanovehicles Equipped with Triptycene-Fused Unidirectional Light-Driven Molecular Motors
- Design, Synthesis and Antitumor Activity Evaluation of Novel Dual G9a/EZH2 Inhibitors
- Engineered etoposide-prednisolone co-nanocrystals for synergistic antitumor efficacy enhancement
BibTeX
@article{calin2026peptidedirected,
title = {{Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity}},
author = {Manuela Calin and Galyna Bila and Ileana Manduteanu and Rostyslav Bilyy},
journal = {View},
year = {2026},
month = oct,
doi = {10.1002/viw.20260015},
url = {https://doi.org/10.1002/viw.20260015},
note = {CC BY},
}
RIS
TY - JOUR
TI - Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity
AU - Manuela Calin
AU - Galyna Bila
AU - Ileana Manduteanu
AU - Rostyslav Bilyy
PY - 2026
DA - 2026/10/26
JO - View
DO - 10.1002/viw.20260015
UR - https://doi.org/10.1002/viw.20260015
AB - Tumors often develop an immune phenotype that closely resembles that of their host, fostering strong immune tolerance. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS). This oxidative vulnerability can be exploited by using ROS‐enhancing compounds that oxidize tumor antigens, offering a promising approach to disrupt immune tolerance and convert immunologically “cold” tumors into “hot” ones. This perspective synthesizes recent findings focused on controlled ROS generation within the tumor microenvironment to induce tumor destruction and stimulate antitumor immunity. While many ROS enhancers are based on small molecules, liposome‐based targeted delivery systems offer a versatile and efficient platform for tumor‐selective transport. Among these, peptide‐functionalized nanovehicles (liposomes and lipid nanoemulsions) stand out for their enhanced targeting precision and design flexibility, allowing tailored delivery strategies. Advances in the design of peptide‐functionalized nanovehicles reveal their potential to trigger ROS‐dependent immune activation, highlighting their promise for integrated immuno‐oncology approaches. By combining targeted delivery with oxidative modulation, these nanoplatforms provide a powerful strategy for reprogramming the tumor microenvironment and amplifying immune responses against therapy‐resistant tumors.
SN - 2688-268X
SN - 2688-3988
ER -